Preventive agents and targeted therapies directed at estrogen receptor, progesterone receptor, and human epidermal growth factor 2 receptor (HER2/neu) have resulted in improved clinical outcomes for many women with breast cancer, but formidable challenges remain in treating tumors that do not express these molecular targets. This evidence concerns the gene ESR1 and breast carcinoma.